Skip to main content

Cytokinetics Value Stock - Dividend - Research Selection


ISIN: US23282W6057, WKN: A1W1KK

Market price date: 24.05.2021
Market price: 22,75 USD

Cytokinetics Fundamental data and company key figures of the share

Annual reports in USD
Key figures 02-03-2021
Cash flow
Net operating cash flow 8.943.000
Capital Expenditures -11.052.000
Free cash flow -2.109.000
Balance sheet
Total Equity 113.383.000
Liabilities & Shareholders equity 533.803.000
Income statement
Net income -127.290.000
Eps (diluted) -1,970
Diluted shares outstanding 71.015.200
Net sales/revenue 55.828.000

Fundamental ratios calculated on: 24-05-2021

Key figures 24-05-2021
Cash flow
P/C 180,66
P/FC -766,05
Balance sheet
Income statement
Div. Yield0,00%

Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.

Market Capitalization1.615.595.776,00 USD
IndicesNASDAQ Comp.
Raw Data SourceUS GAAP in Millionen USD
Stock Split2013-06-25,1.0000/6.0000

Description of the company

Cytokinetics, Incorporated (Cytokinetics) is a biopharmaceutical company focused on the discovery and development of small molecule therapeutics that modulate muscle function for the potential treatment of serious diseases and medical conditions. The Company´s research and development programs relating to the biology of muscle function are directed to small molecule modulators of the contractility of cardiac, skeletal and smooth muscle. The cardiac muscle contractility program is focused on cardiac sarcomere, the basic unit of muscle contraction in the heart. Its lead drug candidate CK-2017357 is subject of a Phase IIa clinical trials program. CK-2017357 is useful in treating diseases or medical conditions associated with skeletal muscle weakness or wasting. In March 2010, CK-2017357 received an orphan drug designation from the FDA for the treatment of amyotrophic lateral sclerosis.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources::,,